Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–312.

Article  PubMed  Google Scholar 

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.

Article  Google Scholar 

Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137–51.

Article  CAS  PubMed  Google Scholar 

Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61:4–6.

CAS  PubMed  Google Scholar 

Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28:3243–56.

Article  PubMed  Google Scholar 

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. AJP. 2006;163:1905–17.

Article  Google Scholar 

Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26:222–32.

Article  PubMed  Google Scholar 

Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002;7:S23–S28.

Article  CAS  PubMed  Google Scholar 

Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry. 2000;61:712–21.

Article  CAS  PubMed  Google Scholar 

Kornhuber J, Zoicas I. Neuropeptide Y as alternative pharmacotherapy for antidepressant-resistant social fear. IJMS. 2020;21:8220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, et al. Acid sphingomyelinase–ceramide system mediates effects of antidepressant drugs. Nat Med. 2013;19:934–8.

Article  CAS  PubMed  Google Scholar 

Kornhuber J, Müller CP, Becker KA, Reichel M, Gulbins E. The ceramide system as a novel antidepressant target. Trends Pharmacol Sci. 2014;35:293–304.

Article  CAS  PubMed  Google Scholar 

Müller CP, Reichel M, Mühle C, Rhein C, Gulbins E, Kornhuber J. Brain membrane lipids in major depression and anxiety disorders. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2015;1851:1052–65.

Article  PubMed  Google Scholar 

Schneider M, Levant B, Reichel M, Gulbins E, Kornhuber J, Müller CP. Lipids in psychiatric disorders and preventive medicine. Neurosci & Biobehav Rev. 2017;76:336–62.

Article  CAS  Google Scholar 

Albouz S, Le Saux F, Wenger D, Hauw JJ, Baumann N. Modifications of sphingomyelin and phosphatidylcholine metabolism by tricyclic antidepressants and phenothiazines. Life Sci. 1986;38:357–63.

Article  CAS  PubMed  Google Scholar 

Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, et al. High activity of acid sphingomyelinase in major depression. J Neural Transm. 2005;112:1583–90.

Article  CAS  PubMed  Google Scholar 

Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, et al. Identification of new functional inhibitors of acid sphingomyelinase using a Structure−Property−Activity relation model. J Med Chem. 2008;51:219–37.

Article  CAS  PubMed  Google Scholar 

Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, et al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26:9–20.

Article  CAS  PubMed  Google Scholar 

Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS ONE. 2011;6:e23852.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoertel N, Sánchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. 2021;26:7098–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot A-S, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199–212.

Article  CAS  PubMed  Google Scholar 

Hoertel N, Sánchez‐Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, et al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID‐19: an observational multicenter study. Clin Pharma Ther. 2021;110:1498–511.

Article  CAS  Google Scholar 

Carpinteiro A, Gripp B, Hoffmann M, Pöhlmann S, Hoertel N, Edwards MJ, et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021;296:100701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4:e2136510.

Article  PubMed  Google Scholar 

Jittamala P, Boyd S, Schilling WHK, Watson JA, Ngamprasertchai T, Siripoon T, et al. Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV). eClinicalMedicine. 2025;80:103036.

Article  PubMed  PubMed Central  Google Scholar 

Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2022;27:307–14.

Article  CAS  PubMed  Google Scholar 

Péricat D, Leon-Icaza SA, Sanchez Rico M, Mühle C, Zoicas I, Schumacher F, et al. Antiviral and anti-inflammatory activities of fluoxetine in a SARS-CoV-2 infection mouse model. IJMS. 2022;23:13623.

Article  PubMed  PubMed Central  Google Scholar 

Thümmler L, Beckmann N, Sehl C, Soddemann M, Braß P, Bormann M, et al. Fluoxetine and sertraline potently neutralize the replication of distinct SARS-CoV-2 variants. Viruses. 2024;16:545.

Article  PubMed  PubMed Central  Google Scholar 

Wannigama DL, Hurst C, Phattharapornjaroen P, Hongsing P, Sirichumroonwit N, Chanpiwat K, et al. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial. eClinicalMedicine. 2024;70:102517.

Article  PubMed  PubMed Central  Google Scholar 

Fritz BA, Hoertel N, Lenze EJ, Jalali F, Reiersen AM. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. 2022;12:341.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoertel N, Rezaei K, Sánchez-Rico M, Delgado-Álvarez A, Kornhuber J, Gulbins E, et al. Medications modulating the acid sphingomyelinase/ceramide system and 28-day mortality among patients with SARS-CoV-2: An observational study. Pharmaceuticals. 2023;16:1107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoertel N, Sánchez-Rico M, Herrera-Morueco JJ, De La Muela P, Gulbins E, Kornhuber J, et al. Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: Results from 49,089 COVID-19 inpatients. Mol Psychiatry. 2022;27:1278–80.